Open AccessPopulation Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
Author(s) -
Makiko Tohi,
Koichiro Irie,
Tomoyuki Mizuno,
Hiroyuki Okuyoshi,
Masaki Hirabatake,
Hiroaki Ikesue,
Nobuyuki Muroi,
Masashi Eto,
Shoji Fukushima,
Keisuke Tomii,
Tohru Hashida
Publication year - 2022
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000996
Subject(s) - nivolumab , medicine , lung cancer , pharmacokinetics , renal function , population , oncology , confidence interval , renal cell carcinoma , urology , cancer , gastroenterology , immunotherapy , environmental health
Nivolumab is an antiprogrammed death-1 (PD-1) antibody used for immuno-oncological therapy of various cancers, including nonsmall cell lung cancer (NSCLC). This study aimed to characterize the real-world population pharmacokinetics (PK) of nivolumab in patients with NSCLC.